BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30179268)

  • 21. Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
    Knoll BM; Seiter K
    Infection; 2018 Jun; 46(3):409-418. PubMed ID: 29388066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
    Chen M; Turhan AG; Ding H; Lin Q; Meng K; Jiang X
    Oncotarget; 2017 Jul; 8(27):43662-43677. PubMed ID: 28599273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre.
    Alizadeh H; Jaafar H; Rajnics P; Khan MI; Kajtár B
    Leuk Res; 2015 Jan; 39(1):47-51. PubMed ID: 25455655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor.
    Zhou L; You JH; Wu W; Li JM; Shen ZX; Wang AH
    Leuk Res; 2013 Oct; 37(10):1216-21. PubMed ID: 23937984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
    Thomas X; Heiblig M
    Expert Opin Drug Discov; 2016 Nov; 11(11):1061-1070. PubMed ID: 27548716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.
    Bao F; Munker R; Lowery C; Martin S; Shi R; Veillon DM; Cotelingam JD; Nordberg ML
    Mol Diagn Ther; 2007; 11(4):239-45. PubMed ID: 17705578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
    Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
    Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
    Elnair R; Galal A
    BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
    Neuendorff NR; Burmeister T; Dörken B; Westermann J
    Ann Hematol; 2016 Aug; 95(8):1211-21. PubMed ID: 27297971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
    Lai Y; Qin Y; Huang X; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glivec and CML: a lucky date.
    Saglio G; Cilloni D; Rancati F; Boano L
    J Biol Regul Homeost Agents; 2004; 18(2):246-51. PubMed ID: 15739279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes of the Pregnancies with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era and Literature Review.
    Castillo DR; Park D; Mehta A; Kaur S; Nguyen A; Akhtari M
    Hematol Rep; 2022 Mar; 14(1):45-53. PubMed ID: 35323179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon-alpha therapy for chronic myeloid leukemia during pregnancy.
    Regierer AC; Schulz CO; Kuehnhardt D; Flath B; Possinger K
    Am J Hematol; 2006 Feb; 81(2):149-50. PubMed ID: 16432865
    [No Abstract]   [Full Text] [Related]  

  • 37. Pregnancy in chronic myeloid leukemia patients treated with alpha interferon.
    Al Bahar S; Pandita R; Nath SV
    Int J Gynaecol Obstet; 2004 Jun; 85(3):281-2. PubMed ID: 15145269
    [No Abstract]   [Full Text] [Related]  

  • 38. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ; Li W; Kong LH; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells.
    Müller-Tidow C; Kiehl M; Sindermann JR; Probst M; Banger N; Zühlsdorf M; Chou TC; Berdel WE; Serve H; Koch OM
    Int J Oncol; 2003 Jul; 23(1):151-8. PubMed ID: 12792788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.